Prognostic value of P-selectin and sST2 in patients with multiple myeloma

Authors

DOI:

https://doi.org/10.14739/2409-2932.2022.3.266453

Keywords:

P-selectin, sST2, cardiovascular risk, multiple myeloma, survival, prognosis

Abstract

Cardiac involvement is one of the most important prognostic markers in multiple myeloma. However, prognostic value of novel biomarkers, such as soluble suppression of tumorigenicity 2 (sST2), P-selectin is unknown in multiple myeloma.

The aim of the work was to investigate the additive predictive effects of novel biomarkers P-selectin and sST2 for cardiovascular events of multiple myeloma patients.

Materials and methods. Levels of P-selectin and sST2 were after anticancer treatment in a total of 67 multiple myeloma patients. The median follow-up duration of the censored cases was 14.0 (11.4–19.1) months. A total of 4 deaths occurred during the follow-up period. ELISA method for measurements of circulating level of P-selectin and sST2 was used.

Results. During follow-up, 36 cardiovascular events and 2 deaths unrelated to cardiovascular events were recorded in 18 (26.9 %) patients. During the study, patients were hospitalized 10 times due to cardiovascular disease. At baseline patients with MM and cardiovascular events which appeared during the observation period had higher levels of P-selectin (P < 0.01), sST2 (P = 0,018), compared to patients without cardiovascular events.

Two novel biomarkers, P-selectin and sST2 showed satisfactory predictive performances for one-year cardiovascular events from ROC analysis. Best cut-off values for predicting one-year cardiovascular events were selected (for sST2 – 31.05 ng/ml, with a sensitivity of 71.5 % and a specificity of 89.8 %; for P-selectin – 54.21 ng/ml, with a sensitivity of 69.6 % and a specificity of 86.2 %). The combination of biomarkers had better prognostic properties compared to P-selectin.

Conclusions. In patients with confirmed multiple myeloma, the biomarkers P-selectin and sST2 showed significant prognostic properties in the occurrence of cardiovascular events during 1 year of follow-up.

Author Biographies

M. O. Panasenko, Zaporizhzhia State Medical University, Ukraine

PhD-student of the Department of Internal Diseases 3

B. B. Samura, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Internal Diseases 3

S. Ya. Dotsenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Internal Disease 3

References

Plummer, C., Driessen, C., Szabo, Z., & Mateos, M.-V. (2019). Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer Journal, 9(3). https://doi.org/10.1038/s41408-019-0183-y

Dorizzi, R. M., Caputo, M., Ferrari, A., Lippa, L., & Rizzotti, P. (2002). Comparison of Serum and Heparin-Plasma Samples in Different Generations of Dimension Troponin I Assay. Clinical Chemistry, 48(12), 2294-2296. https://doi.org/10.1093/clinchem/48.12.2294

Maries, L., & Manitiu, I. (2013). Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP) : review article. Cardiovascular Journal of Africa, 24(7), 286-289. https://doi.org/10.5830/cvja-2013-055

Samura, B., & Panasenko, M. (2022). SST2 as a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian Medical News, 326, 18-22.

Panasenko, M. O., Samura, B. B., & Dotsenko, S. Ya. (2022). Znachennia R-selektynu v prohnozi kardiovaskuliarnykh podii u patsiientiv iz mnozhynnoiu miielomoiu [Value of P-selectin in the prognosis of cardiovascular events in patients with multiple myeloma]. Current issues in pharmacy and medicine: science and practice, 15(2), 186-189. [in Ukrainian]. https://doi.org/10.14739/2409-2932.2022.2.259829

Mor-Avi, V., & Lang, R. M. (2011). Transthoracic Three-Dimensional Echocardiography. In Advanced Approaches in Echocardiography (pp. 1-20). Elsevier. https://doi.org/10.1016/B978-1-4377-2697-8.00001-8

Ministry of Health of Ukraine. (2015, November 2). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy "Mnozhynna miieloma" [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care «Multiple myeloma» (No. 710)]. [in Ukrainian]. https://dec.gov.ua/wp-content/uploads/images/dodatki/2015_710_MM/2015_710_YKPMD_MM.pdf

Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6), 1334-1357. https://doi.org/10.1161/hypertensionaha.120.15026

Wright, J. J., & Tylee, T. S. (2016). Pharmacologic Therapy of Type 2 Diabetes. Medical Clinics of North America, 100(4), 647-663. https://doi.org/10.1016/j.mcna.2016.03.014

Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., & ESC Scientific Document Group (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal, 37(36), 2768-2801. https://doi.org/10.1093/eurheartj/ehw211

Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., Fonseca, R., Zeldenrust, S. R., McGregor, C. G. A., & Jaffe, A. S. (2004). Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 22(18), 3751-3757. https://doi.org/10.1200/jco.2004.03.029

Seki, K., Sanada, S., Kudinova, A. Y., Steinhauser, M. L., Handa, V., Gannon, J., & Lee, R. T. (2009). Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling. Circulation: Heart Failure, 2(6), 684-691. https://doi.org/10.1161/circheartfailure.109.873240

Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N. J., & Lee, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation, 117(6), 1538-1549. https://doi.org/10.1172/jci30634

Gruson, D., Lepoutre, T., Ahn, S. A., & Rousseau, M. F. (2014). Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. International Journal of Cardiology, 172(1), e250-e252. https://doi.org/10.1016/j.ijcard.2013.12.101

Published

2022-11-15

How to Cite

1.
Panasenko MO, Samura BB, Dotsenko SY. Prognostic value of P-selectin and sST2 in patients with multiple myeloma. CIPM [Internet]. 2022Nov.15 [cited 2023Dec.8];15(3):307-12. Available from: http://pharmed.zsmu.edu.ua/article/view/266453

Issue

Section

Original research